September 27, 2022
Press release
General Incorporated Association EFPIA Japan(European Federation of Pharmaceutical Industries and Associations)

EFPIA Japan Announces Winners for Fifth “PASE AWARD”,Patient Organization Support Program
TOKYO – 16 September 2022 – General Incorporated Association EFPIA Japan (European
Federation of Pharmaceutical Industries and Associations) announced today winners for its Fifth
PASE AWARD, selecting patient groups that particularly contribute to the evolution of Japan’s patientadvocacy and offering grants totalling 1.10 million yen. This year’s theme is “Activities led by patientorganizations for realization of patients’ better medical treatment and lives under the New Normal”,
and EFPIA Japan started to call for entries from patient organizations in May and received
applications from a total of 11 patient organizations by July 8. This year the “Grand Award” has been
given to two groups, and the “Honor Award” has been given to three groups as below.

Fifth PASE AWARD winner organizations
Overview of application / proposal

Grant(JPY)Grand Certified Non-profit Organization
Award KIBOUNOKAI

Creation of an educational booklet on gastric cancer

500,000

Honor Specified Non-profit Corporation
Award Cancer Forum Yamanashi

Internet Radio (I.R.)" to create a mechanism to receiveand empathize with thoughts and feelings of patients
150,000
and their families

Honor General Incorporated AssociationAward Tekuteku Peer Net

Creation of a booklet on how to cope with diseaseand child rearing under new normal

150,000

Honor Non-profit Organization Decoboco
Award Life Design

Case studies on communication gap between people
with developmental disabilities and their surroundings

150,000

Specified Non-profit Corporation
Honor
Head and Neck Cancer PatientAward
Support Network

Survey in patients and symposiums for both patientsand healthcare professionals in collaboration with other 150,000
head and neck cancer patient associations

AwardAward winning organization

EFPIA Japan Chair Takahiko Iwaya said, "I would like to thank all the patient organizations thatapplied for the Fifth PASE AWARD. It has been more than two years since the outbreak of COVID-19,
and patient groups continue to make progress despite many restrictions associated with thepandemic. All the proposals received this time were very meaningful especially in these difficult times,
and the selection on the Grand Award was extremely difficult. EFPIA Japan will continue to support
the activities of these patient groups ultimately to ensure that patients in Japan have access to thelatest medical care.”

EFPIA JapanTokyo Opera City Tower, 3-20-2, Nishi Shinjuku, Shinjuku-ku, Tokyo, Japan

About the EFPIA Japan Patient Organization Support Program “PASE”“PASE (Patient Advocacy Support by EFPIA Japan)” is a patient organization support program
established in 2017 with the goal of realizing the patient-centered thinking of EFPIA Japan. PASE wasconceived to further encourage patient group activities in Japan, and to support the healthcare
environment surrounding patients to evolve, so that it better reflects patients’ voices and patientneeds. As part of PASE, EFPIA Japan decided to conduct the PASE AWARDs, in which grants of 1.10
million yen this year will be awarded to organizations that contribute to the evolution of patientadvocacy (activities to protect patient rights).
About the Fifth “PASE AWARD”
More than two years have passed since the outbreak of the COVID-19 pandemic. This impacts ourlives and forces us to change our lifestyles in many ways. In such a situation, patient groups andindividual patients have come to be required to adapt to new modes of lives, known as the “NewNormal”. The fifth PASE AWARD this year called for activity plans of patient organizations to empower
patients to have appropriate diagnosis, treatment and disease control while adapting to new lifestyles
and preventing COVID-19 as well as activity plans to achieve healthcare policies that reflect patientvoices under the New Normal. The draft plans were reviewed and selection was based on four
evaluation criteria: “Having a clear purpose as a patient group and clear goals with KPIs”, “Showingconcrete deliverables for achieving purpose in past activities”, “Having a specific implementation planof activity for using grants (including how to use grants)”, “Being able to cooperate in disseminating theresults of activities using grants (Allowing for posting on the EFPIA Japan website, notification andreporting on their own website)”. The organization that won the Grand Award will be offered a grant of500,000 yen and be invited to attend the presentation ceremony on October 6, 2021. The four groups
that won the Honor Award will be offered a grant of 150,000 yen. If you wish to participate in the Fifth
PASE Award ceremony, please refer to the invitation letter, "EFPIA Day 2022 Special Press
Conference," issued on September 15.
The Fifth PASE Final Selection Committee Members

Mr. Takeo Nakayama (Kyoto University Faculty of Medicine, Professor of Health Informatics)
Mr. Takahiko Iwaya, EFPIA Japan Chair (Sanofi K.K.)
Mr. Leo Lee, EFPIA Japan Vice Chair (Novartis Co., Ltd.)
Mr. Paul Lirette, EFPIA Japan Board Member (GlaxoSmithKline K.K.)
Mr. Kana Matsumura, EFPIA Japan Governance and Legal Committee Chair (Nippon BoehringerIngelheim Co., Ltd.)
About EFPIA Japan
Established in April 2002, EFPIA Japan represents 23 R&D-based European pharmaceuticalcompanies operating in Japan. In 2021, combined sales from the member companies accountedfor roughly 26% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to“Contribute to healthcare and patients in Japan through the early introduction of innovative
medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in orderto improve Japanese healthcare for all.

EFPIA JapanTokyo Opera City Tower, 3-20-2, Nishi Shinjuku, Shinjuku-ku, Tokyo, Japan

About the European Federation of Pharmaceutical Industries and Associations (EFPIA)
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents thebiopharmaceutical industry operating in Europe. Through its direct membership of 37 nationalassociations, 38 leading pharmaceutical companies and a growing number of small and medium-sizedenterprises (SMEs), EFPIA’s mission is to create a collaborative environment that enables ourmembers to innovate, discover, develop and deliver new therapies and vaccines for people acrossEurope, as well as contribute to the European economy.
Details can be found below.
http://efpia.jp/ (EFPIA Japan)
http://www.efpia.eu (EFPIA)

Inquires to：
Hitoshi Fujita
EFPIA Japan Public Relations Committee, person incharge of PASE
Novartis Pharma K.K.
Toranomon Hills Mori tower
1-23-1 Toranomon, Minato-ku, Tokyo 105-6333
TEL: 090-9837-4326
E-mail: hitoshi.fujita@novartis.com

Naomi Sakai
EFPIA Japan Patient Committee, person in charge ofPASE
Nippon Boehringer Ingelheim Co., Ltd.
ThinkPark Tower
2-1-1 Osaki, Shinagawa-ku, Tokyo 141-6017
TEL: 03-6417-2489
E-mail: naomi.sakai@boehringer-ingelheim.com

EFPIA JapanTokyo Opera City Tower, 3-20-2, Nishi Shinjuku, Shinjuku-ku, Tokyo, Japan